

Amendment 018 Email, September 21, 2012

- Ducord

From: Gavin, Denise K
Sent: Friday, September 21, 2012 2:25 PM
To: Davidson, Mark
Subject: FW: Amendment 018
Mark please add this to EDR. thank you. d

From: Gavin, Denise K
Sent: Friday, September 21, 2012 2:24 PM
To: 'Bruce Burnett, Ph.D.'; Amanda Parrish, Ph.D.
Cc: Davidson, Mark; Wonnacott, Keith
Subject: RE: Amendment 018
Bruce

In addition to the validation and comparability report of the ---(b)(4)--- thawing procedure, please include also submit the following outstanding items:

1) the revised stability protocol (not data) with revised acceptance criteria (i.e. (b)(4) units must past sterility) and additional information regarding the use of -----(b)(4)----- thawing processes and how that will or will not affect % recoveries.

2) the revised Process Validation protocol which accurately reflects the method used to thaw units.

"And as mentioned above, STCL-PROC-034 was listed in the process validation report submitted in Amendment 14 on August 15, 2012. This was incorrect and STCL-SOP-028 and STCL-PROC-036 should have been listed. This error will be corrected and the amended validation report submitted to the BLA."

3) Please comment as to whether you still intend to include documents with Ducord, that are not FDA approved (i.e. AABB COI).

You previously stated that "Communication with FACT suggests that while the COI is currently required, revised standards are being circulated for review in September 2012 with the following change:

E4.5 A circular of information or package insert and instructions for handling, thawing, and using the CB unit, including short-term storage and preparation for administration, shall accompany the CB unit. (Bolding and italics added for emphasis).

Thank you,

Denise

Denise K. Gavin, Ph.D.

Expert Biologist

Gene Therapy Branch

FDA/CBER/OCTGT/DCGT

Rockville, MD 20852
301-827-5102

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."

The security of information transmitted through this email can not be guaranteed. Information contained in this email may not reflect the official policy of the FDA and is therefore not legally binding.

From: Bruce Burnett, Ph.D. [mailto:bruce.burnett@duke.edu]
Sent: Friday, September 21, 2012 12:11 PM
To: Gavin, Denise K; Amanda Parrish, Ph.D.
Cc: Davidson, Mark; Wonnacott, Keith
Subject: RE: Amendment 018
Denise,

Yes, we do have a report, which I have attached and will submit formally to the BLA today.

Bruce

Bruce K. Burnett, PhD, RAC
Director of Regulatory Affairs
Duke Translational Medicine Institute
Duke University School of Medicine
Phone: 919 668-7178

From: Gavin, Denise K [mailto:Denise.Gavin@fda.hhs.gov]
Sent: Friday, September 21, 2012 12:07 PM
To: Bruce Burnett, Ph.D.; Amanda Parrish, Ph.D.
Cc: Davidson, Mark; Wonnacott, Keith
Subject: Amendment 018

Hi Bruce

When do you plan to submit the information related to STCL-SOP-036 validation and comparability between -----(b)(4)----- Thaw/wash procedures used for stability protocol?

This information is necessary since STCL-SOP-036 is part of the stability protocol to extend the expiration date on a yearly basis. I do not have data to support control of that procedure for establishing stability going forward.

Based on an email from JK on 9-17-12, I expected this information on 18SEPT2012 or at least in the amendment submitted today, but I did not see it there. The stability protocol needs to be finalized today or a revision submitted as a supplement. I need this information by 1 pm today to complete our review.

This information can also be submitted as a supplement to the BLA if you are not ready to submit today. We will simply change our memo to state that the stability protocol is not yet acceptable and will be revised as a supplement to include the above requested information. This may also be the case it upon reviewing the data I have additional questions.

I am hoping this submission was just lost in the rush to get the thaw wash instructions revised.

Please advise as to your plans.

There are other minor issues that need to be addressed and I will send another email later with that information.

Thank you,

Denise

Denise K. Gavin, Ph.D.
Expert Biologist
Gene Therapy Branch
FDA/CBER/OCTGT/DCGT
Rockville, MD 20852
301-827-5566

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."

The security of information transmitted through this email can not be guaranteed. Information contained in this email may not reflect the official policy of the FDA and is therefore not legally binding.

<https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/default.htm>

Page Last Updated: 11/02/2012

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

Language Assistance Available: [Español](#) | [繁體中文](#) | [Tiếng Việt](#) | [한국어](#) | [Tagalog](#) | [Русский](#) | [ةيبرعلا](#) | [Kreyòl Ayisyen](#) | [Français](#) | [Polski](#) | [Português](#) | [Italiano](#) | [Deutsch](#) | [日本語](#) | [عسراف](#) | [English](#)